



Prof Zobair M. Younossi

President of Inova Medicine, Inova Health System and the Chairman and Professor of Medicine, Inova Fairfax Medical Campus.

Prof Younossi is the President of Inova Medicine, Inova Health System and the Chairman and Professor of Medicine, Inova Fairfax Medical Campus. He is also the Chairman of Clinical Research, Inova Health System.

Prof Younossi earned his medical degree from the University of Rochester School of Medicine and Dentistry in Rochester, New York (Alpha Omega Alpha, 1989), and completed his residency in internal medicine as well as a fellowship in gastroenterology and hepatology at Scripps Clinic and Research Foundation in La Jolla, California. During his residency and fellowship, he earned his Master of Public Health degree from San Diego State University (SDSU) School of Public Health in San Diego, California, being awarded both the Hanlon Award and Outstanding Student Award for SDSU. He then served as the Staff Hepatologist and Senior Researcher at the Cleveland Clinic Foundation, Cleveland, Ohio (1995– 2000). In 2000, Prof Younossi joined Inova Health System to establish the Center for Liver Diseases.

Prof Younossi is an internationally known hepatologist who has pioneered research in NAFLD and has been a leader in the field of patient-reported outcomes, economic assessment and outcomes research in liver disease. He is the Chair of Global NASH Council and the Global Liver and NASH Registries. His research in both NAFLD and outcomes research is extensively cited and he is a highly sought-after speaker for national and international scientific meetings. Prof Younossi specializes in hepatology and gastroenterology and has authored over 600 articles, 3 books, 6 journal supplements and has delivered over 430 faculty lectures in national and international meetings. Prof Younossi has also served as the co-editor of Liver International, Associate Editor of Journal of Hepatology and the editorial board of a number of important medical journals. He has represented the American Association of Liver Disease and American Gastroenterological Association at different congressional meetings.

Insights into NAFLD burden and epidemiology. What does the data tell us? Global insights

What you will learn:

Burden of NAFLD and how we can interpret the available data:

- Worldwide prevalence of NAFLD is very high particularly amongst people with diabetes.
- Increasing number of NAFLD patients are progressing to NASH.
- NAFLD is now the most frequent cause of liver disease worldwide and NASH is the potentially progressive type of NAFLD.
- The high burden of NASH will have important clinical and economic consequences.